GPCM
IMUX icon

Granite Point Capital Management’s Immunic IMUX Stock Holding History

Granite Point Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-19,803
Closed -$2.4M – 178
2020
Q2 		$2.4M Buy
+19,803
New +$2.01M 0.12% 79

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Granite Point Capital Management's IMUX Position: Q3 2020 in Review

Granite Point Capital Management sold out of Immunic (IMUX) in Q3 2020, closing a stake of 19,803 shares — an estimated $2.4M sold.

Granite Point Capital Management first reported a position in IMUX in Q2 2020 and held it in 1 quarter. The position peaked at $2.4M in Q2 2020. 66 funds tracked by Wall St. Rank hold IMUX as of Q3 2020.

  • Granite Point Capital Management reported no remaining Immunic position as of Q3 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 19,803 Immunic shares in Q3 2020, an estimated $2.4M.
  • Granite Point Capital Management first reported a position in Immunic in Q2 2020 and held it in 1 quarter.
  • Granite Point Capital Management's Immunic position peaked at $2.4M in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Immunic as of Q3 2020.

Based on Granite Point Capital Management's 13F filing for Q3 2020, filed 6 Nov 2020.